34 related articles for article (PubMed ID: 11848529)
1. Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Minutoli L; Rinaldi M; Marini H; Irrera N; Crea G; Lorenzini C; Puzzolo D; Valenti A; Pisani A; Adamo EB; Altavilla D; Squadrito F; Micali A
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27529214
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell secretion of soluble factor(s) for specific immunosuppression.
Kano A
Sci Rep; 2015 Mar; 5():8913. PubMed ID: 25746680
[TBL] [Abstract][Full Text] [Related]
3. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women.
Xu Y; Deng Q; He B; Pan Y; Li R; Gao T; Sun H; Song G; Wang S; Cho WC
Tumour Biol; 2014 Sep; 35(9):9147-61. PubMed ID: 24916571
[TBL] [Abstract][Full Text] [Related]
4. α-blockade, apoptosis, and prostate shrinkage: how are they related?
Chłosta P; Drewa T; Kaplan S
Cent European J Urol; 2013; 66(2):189-94. PubMed ID: 24579025
[TBL] [Abstract][Full Text] [Related]
5. Serum markers of apoptosis decrease with age and cancer stage.
Kavathia N; Jain A; Walston J; Beamer BA; Fedarko NS
Aging (Albany NY); 2009 Jul; 1(7):652-63. PubMed ID: 20157546
[TBL] [Abstract][Full Text] [Related]
6. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
7. Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
Yamanegi K; Yamane J; Hata M; Ohyama H; Yamada N; Kato-Kogoe N; Futani H; Nakasho K; Okamura H; Terada N
J Cancer Res Clin Oncol; 2009 Jul; 135(7):879-89. PubMed ID: 19066961
[TBL] [Abstract][Full Text] [Related]
8. Tumor escape mechanisms in prostate cancer.
Miller AM; Pisa P
Cancer Immunol Immunother; 2007 Jan; 56(1):81-7. PubMed ID: 16362411
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
10. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
Hall MC; Roehrborn CG; McConnell JD
Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble Fas level for detection and staging of prostate cancer.
Furuya Y; Fuse H; Masai M
Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
[TBL] [Abstract][Full Text] [Related]
12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
13. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
14. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
